EMC Digitals · Clinical Decision Support

Vasoactive Selector — Cardiogenic Shock

Logic derived from Riccardi et al., Eur J Heart Fail 2024;26:411–431 (Figures 2–3, Table 2). For clinician use alongside bedside judgment and haemodynamic monitoring — not a substitute for either.

Vasopressor treatment stage

MECHANICAL EFFICIENCY
Mechanical efficiency
Mechanical inefficiency
Metabolic inefficiency

Patient profile

Select the closest match — recommendations update live.
Aetiology
Haemodynamic profile
Chronic β-blocker therapy
Renal function
Bradycardia risk

Recommendation

AMI-CS Hypotension prevails Mechanical efficiency

First-line

Rescue phase

If refractory / second-line

Escalation
Scope of evidence. Per the source review: no pharmacological therapy has proven mortality benefit in cardiogenic shock (DOREMI, LIDO, SURVIVE, SOAP-II and the Cochrane meta-analysis were consistently neutral or only hypothesis-generating). This tool encodes a therapeutic algorithm built from a mix of RCTs and observational registries where trial data is absent, and is intended to structure — not replace — bedside decision-making, invasive haemodynamic assessment, and escalation planning to MCS.